增殖性糖尿病视网膜病变玻璃体切除术前贝伐珠单抗给药时机比较:一项随机对照试验
该随机对照试验将156例因增殖性糖尿病视网膜病变相关并发症需行玻璃体切除术的患者分为两组,A组术前1-3天、B组术前5-10天接受玻璃体腔注射贝伐珠单抗2.5 mg/0.1 mL。完成6个月随访的125例中,B组最终最佳矫正视力更优(P=0.033)且术后并发症更少(P=0.018),结论支持术前5-10天给药。
要点
- B组(术前5-10天给药)最终最佳矫正视力优于A组(术前1-3天给药),P=0.033。
- B组术后并发症发生率低于A组,P=0.018。
- 两组术中手术时间、术中并发症及非计划玻璃体切除术发生率无显著差异。
核心结论
- 该随机临床试验表明,与术前1-3天给药相比,术前5-10天接受玻璃体腔注射贝伐珠单抗治疗增殖性糖尿病视网膜病变相关并发症,6个月时术后结局更优。
研究设计与样本
- 随机临床试验,156例因增殖性糖尿病视网膜病变相关并发症需行玻璃体切除术的患者前瞻性随机分为两组。
- A组术前1-3天接受玻璃体腔注射贝伐珠单抗2.5 mg/0.1 mL,B组术前5-10天接受玻璃体腔注射贝伐珠单抗2.5 mg/0.1 mL。
- 主要结局为6个月随访时最佳矫正视力,次要结局包括术中手术时间、术中并发症、术后并发症及6个月随访期间非计划玻璃体切除术发生率。
- 125例受试者接受了玻璃体切除术并完成6个月随访。
主要发现
- 与A组相比,B组患者最终最佳矫正视力更优(P=0.033),且发生术后并发症的可能性更低(P=0.018)。
- 两组间最终最佳矫正视力的平均差异为0.22 logMAR(95%CI:0.02-0.43,P=0.017)。
- A组最终最佳矫正视力丢失1行及以上logMAR字母行的可能性是B组的3.90倍(95%CI:1.08-17.31,P=0.046)。
- 两组在基线特征、术中手术时间、术中并发症及研究期间非计划玻璃体切除术发生率方面无显著差异。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To assess the optimal interval of preoperative intravitreal bevacizumab (IVB) administration in diabetic subjects undergoing pars plana vitrectomy (PPV) for severe manifestations of active proliferative diabetic retinopathy (PDR). DESIGN: Randomized clinical trial. METHODS: One hundred and fifty-six patients with PDR-related complications requiring PPV were prospectively randomized into 1 of 2 treatment groups: Group A received IVB (2.5 mg/0.1 mL) 1-3 days before PPV, while Group B received IVB (2.5 mg/0.1 mL) 5-10 days before PPV. The primary outcome was best-corrected visual acuity (BCVA) at 6 months follow-up. Secondary outcome measures were intraoperative surgery time, intraoperative complications, postoperative complications, and incidence of unplanned PPV at 6 months follow-up. RESULTS: One hundred and twenty-five subjects underwent PPV and completed the 6-month follow-up interval. Group B patients had better final BCVA (P = .033) and were less likely to have a postoperative complication (P = .018) when compared to Group A patients. The mean difference in final BCVA between groups was 0.22 logMAR (95% confidence interval: 0.02-0.43, P = .017). Group A was 3.90 (95% confidence interval: 1.08-17.31, P = .046) times more likely to have a loss of 1 or more logMAR lines of final BCVA when compared to Group B. There were no significant differences among the treatment groups with regard to baseline features, intraoperative surgery time, intraoperative complications, and incidence of unplanned PPV during the study interval. CONCLUSIONS: This randomized clinical trial demonstrated better postoperative outcomes at 6 months when subjects received preoperative IVB 5-10 days before PPV compared to 1-3 days for the treatment of PDR-related complications.
引用
- Castillo J, Aleman I, Rush SW, et al. Preoperative Bevacizumab Administration in Proliferative Diabetic Retinopathy Patients Undergoing Vitrectomy: A Randomized and Controlled Trial Comparing Interval Variation. Am J Ophthalmol. 2017. PMID: 28860046. doi:10.1016/j.ajo.2017.08.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。